[1]
Fumagalli, C., Betella, I., Ranghiero, A., Guerini-Rocco, E., Bonaldo, G., Rappa, A., Vacirca, D., Colombo, N. and Barberis, M. 2022. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica - Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology. 114, 4 (Sep. 2022), 288-294. DOI:https://doi.org/10.32074/1591-951X-791.